Keywords: datamonitor, expresses, views, celebrex, vs, vioxx, novartis
Datamonitor expresses views on Celebrex vs Vioxx; Novartis ADHD drug
Article | 24 September 2001
Pfizer and Pharmacia have criticized a recent study that claims theirnew selective COX-2 inhibitor Celebrex (celecoxib; Marketletter September 3) may increase ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
